Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRG002 in HER2-mutated NSCLC
NCT05141786Phase 2Unknown
- Sponsor
- Hangzhou Miracogen
- Start
- Dec 2021
- Primary completion
- Dec 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of MRG002 in non-small cell lung cancer (NSCLC), sponsored by Hangzhou Miracogen. Primary endpoint: Objective Response Rate by Independent Review Committee up to 12 months. Status: unknown.
02
Drugs
MRG002
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05141786.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05141786.